We treated IMR-90 cells with the genotoxic chemotherapeutic agents doxorubicin (DOXO), taxol (TAX) or cisplatin (CIS), and measured IL-6 secretion in the presence or absence of an MDM2 inhibitor. The gene discussed is MDM2; the disease is in situ carcinoma.